重症患者基于KDIGO血肌酐标准的分层结局:多中心前瞻性研究的二次分析
该研究为对中国22家三级ICU、19个省市自治区、3063例患者的多中心前瞻性数据库的二次分析,最终纳入1042例,其中AKI 345例,AKI发生率33.11%,AKI患者28天ICU死亡率为13.91%(48/345)。按基线eGFR将AKI分为单纯AKI(PAKI,eGFR≥60 mL×min-1×1.73 m-2)和慢性肾病基础急性加重(AoCKD,eGFR 15-59 mL×min-1×1.73 m-2)。AoCKD患者28天ICU死亡率39.13%(9/23)显著高于PAKI的12.11%(39/322),RRT发生率26.09%(6/23)也显著高于PAKI的4.04%(13/322),28天累积生存率显著更低。多因素Cox分析显示呼吸衰竭入ICU、ICU使用血管活性药物和AoCKD是28天ICU死亡的独立危险因素。
要点
- AKI患者中AoCKD(基线eGFR 15-59 mL×min-1×1.73 m-2)28天ICU死亡率39.13%(9/23),显著高于PAKI的12.11%(39/322)。
- AoCKD患者RRT发生率26.09%(6/23),显著高于PAKI的4.04%(13/322),两组ICU住院时间无显著差异。
- 多因素Cox分析:呼吸衰竭入ICU(HR=4.458,95%CI 1.141-17.413)、ICU使用血管活性药物(HR=5.181,95%CI 2.033-13.199)、AoCKD(HR=5.377,95%CI 1.303-22.186)为28天ICU死亡独立危险因素。
- AoCKD患者较PAKI更老[74(59,77)岁 vs. 58(41,72)岁]、APACHE II更高[23(19,27)vs. 15(11,22)]、基线eGFR更低[49(38,54)vs. 115(94,136)mL×min-1×1.73 m-2],均P<0.01。
- KDIGO血肌酐标准诊断AKI后,结合基线eGFR进一步分层(PAKI与AoCKD)与ICU 28天死亡相关。
适用人群与场景
- 中国19个省市自治区22家三级ICU的多中心前瞻性研究数据库中的重症患者,二次分析最终纳入1042例(AKI 345例,非AKI 697例)。
- PAKI组322例:符合KDIGO-AKI血肌酐标准且基线eGFR≥60 mL×min-1×1.73 m-2。
- AoCKD组23例:符合KDIGO-AKI血肌酐标准且基线eGFR 15-59 mL×min-1×1.73 m-2。
诊断标准与关键阈值
- AKI诊断依据KDIGO-AKI血清肌酐标准(KDIGO-AKISCr)。
- PAKI定义:符合KDIGO-AKISCr标准且基线eGFR≥60 mL×min-1×1.73 m-2。
- AoCKD定义:符合KDIGO-AKISCr标准且基线eGFR 15-59 mL×min-1×1.73 m-2。
研究设计与关键结果
- 研究类型:对China Critical Care Clinical Trial Group(CCCCTG)多中心前瞻性研究数据库的二次分析,涉及中国19个省市自治区22家三级ICU的3063例患者,最终纳入1042例,其中AKI 345例、非AKI 697例。
- AKI发生率为33.11%,AKI患者28天ICU死亡率为13.91%(48/345)。
- AoCKD组较PAKI组年龄更大[74(59,77)岁 vs. 58(41,72)岁]、入ICU时APACHE II更高[23(19,27)vs. 15(11,22)]、基线eGFR更低[49(38,54)vs. 115(94,136)mL×min-1×1.73 m-2]、CCI更高[3(2,4)vs. 0(0,1)]、诊断AKI时峰值SCr更高[412(280,515)vs. 176(124,340)μmol/L],均P<0.01。
- AoCKD组28天ICU死亡率39.13%(9/23)显著高于PAKI组12.11%(39/322),RRT发生率26.09%(6/23)显著高于PAKI组4.04%(13/322),均P<0.01;两组ICU住院时间无显著差异。
- Kaplan-Meier分析显示AoCKD组28天ICU累积生存率显著低于PAKI组(Log-Rank:χ²=5.939,P=0.015)。
- 多因素Cox回归显示呼吸衰竭入ICU(HR=4.458,95%CI 1.141-17.413,P=0.032)、ICU使用血管活性药物(HR=5.181,95%CI 2.033-13.199,P=0.001)、AoCKD(HR=5.377,95%CI 1.303-22.186,P=0.020)是28天ICU死亡的独立危险因素。
证据类型、等级与局限
- 局限:原文未报告局限性。
对床旁实践的改变
- 对符合KDIGO血肌酐标准的AKI重症患者,结合基线eGFR区分PAKI与AoCKD有助于识别28天ICU死亡和RRT风险更高的人群;AoCKD组28天ICU死亡率39.13%(9/23) vs. PAKI组12.11%(39/322)。
- 呼吸衰竭入ICU(HR=4.458,95%CI 1.141-17.413)和ICU使用血管活性药物(HR=5.181,95%CI 2.033-13.199)提示28天ICU死亡风险更高,原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the different outcomes of two types of acute kidney injury (AKI) according to standard of Kidney Disease: Improving Global Outcomes-AKI (KDIGO-AKI), and to analyze the risk factors that affect the prognosis of intensive care unit (ICU) patients in China.
METHODS: A secondary analysis was performed on the database of a previous study conducted by China Critical Care Clinical Trial Group (CCCCTG), which was a multicenter prospective study involving 3 063 patients in 22 tertiary ICUs in 19 provinces and autonomous regions of China. The demographic data, scores reflecting severity of illness, laboratory findings, intervention during ICU stay were extracted. All patients were divided into pure AKI (PAKI) and acute on chronic kidney disease (AoCKD). PAKI was defined as meeting the serum creatinine (SCr) standard of KDIGO-AKI (KDIGO-AKISCr) and the estimated glomerular filtration rate (eGFR) at baseline was ≥ 60 mL×min-1×1.73 m-2, and AoCKD was defined as meeting the KDIGO-AKISCr standard and baseline eGFR was 15-59 mL×min-1×1.73 m-2. All-cause mortality in ICU within 28 days was the primary outcome, while the length of ICU stay and renal replacement therapy (RRT) were the secondary outcome. The differences in baseline data and outcomes between the two groups were compared. The cumulative survival rate of ICU within 28 days was analyzed by Kaplan-Meier survival curve, and the risk factors of ICU death within 28 days were screened by Cox multivariate analysis.
RESULTS: Of the 3 063 patients, 1 042 were enrolled, 345 with AKI, 697 without AKI. The AKI incidence was 33.11%, while ICU mortality within 28 days of AKI patients was 13.91% (48/345). Compared with PAKI patients (n = 322), AoCKD patients (n = 23) were older [years old: 74 (59, 77) vs. 58 (41, 72)] and more critical when entering ICU [acute physiology and chronic health evaluation II (APACHE II) score: 23 (19, 27) vs. 15 (11, 22)], had worse basic renal function [eGFR (mL×min-1×1.73 m-2): 49 (38, 54) vs. 115 (94, 136)], more basic complications [Charlson comorbidity index (CCI): 3 (2, 4) vs. 0 (0, 1)] and higher SCr during ICU stay [peak SCr for diagnosis of AKI (μmol/L): 412 (280, 515) vs. 176 (124, 340), all P < 0.01]. The mortality and RRT incidence within 28 days in ICU of AoCKD patients were significantly higher than those of PAKI patients [39.13% (9/23) vs. 12.11% (39/322), 26.09% (6/23) vs. 4.04% (13/322), both P < 0.01], while no significant difference was found in the length of ICU stay. Kaplan-Meier survival curve analysis showed that the 28-day cumulative survival rate in ICU in AoCKD patients was significantly lower than PAKI patients (Log-Rank: χ 2 = 5.939, P = 0.015). Multivariate Cox regression analysis showed that admission to ICU due to respiratory failure [hazard ratio (HR) = 4.458, 95% confidence interval (95%CI) was 1.141-17.413, P = 0.032], vasoactive agents treatment in ICU (HR = 5.181, 95%CI was 2.033-13.199, P = 0.001), and AoCKD (HR = 5.377, 95%CI was 1.303-22.186, P = 0.020) were independent risk factors for ICU death within 28 days.
CONCLUSIONS: Further detailed classification (PAKI, AoCKD) based on KDIGO-AKISCr standard combined with eGFR is related to ICU mortality in critical patients within 28 days.
参考来源
- Dong G, Qin J, An Y, et al. [Stratified outcomes of "Kidney Disease: Improving Global Outcomes" serum creatinine criteria in critical ill patients: a secondary analysis of a multicenter prospective study]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 32385995. doi:10.3760/cma.j.cn121430-20200218-00192
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。